science
-
NIH officials discuss agency’s Long COVID clinical trials, respond to critiques
“We understand the frustration and respect it completely,” said NIAID program officer and TLC leader Joseph Breen, when asked about the more than a year that’s gone between RECOVER-TLC trials’ announcement and enrolling participants.
-
Live blog: RECOVER-TLC third annual workshop shares updates on Long COVID clinical trials
Leading Long COVID scientists, government officials, and advocates are meeting today and tomorrow in Bethesda, Maryland for the third annual RECOVER-Treating Long COVID (TLC) workshop, hosted by the National Institutes of Health (NIH) and Foundation for the National Institutes of Health (FNIH). At a hotel near the NIH campus, attendees will hear updates on the…
-
Novel drug bezisterim plans for further study in Long COVID. Here’s how the phase 2 trial came together.
Novel anti-inflammatory drug shows early promise in treating Long COVID cognitive symptoms, fatigue, PEM. The study looked at multiple endpoints and consulted with people living with the disease.
-
The real story behind the “October slide”
Changing seasons affect many people with Long COVID, myalgic encephalomyelitis, and other chronic illnesses, but not all in the same way. Research has a long way to go before it can explain the phenomenon.
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Researchers, clinicians, and advocates gathered for the inaugural conference of the International Society for Long COVID and Post-Acute Infection Syndromes in the Netherlands in late August. The four-day event featured hundreds of presentations and posters about trials and disease mechanisms.
-
People with Long COVID demand pause of McMaster University clinical trial
The trial, run by researchers at McMaster University in Canada, is testing the Lightning Process, a pseudoscientific mind-body program that outside experts have heavily criticized.
-
Bezisterim may help with some Long COVID symptoms, drug’s developer reports in early trial results
While the phase 2 clinical trial results, shared by BioVie in a webinar on Tuesday, have yet to be peer-reviewed, investigators say they can inform a confirmatory phase 3 trial.
-
VIPER aims to fast track Long COVID biomarkers. Here’s how it works.
Led by researchers at UCSF, the research program plans to validate promising candidates for noninvasive tests that can be used to advance clinical trials.
-
Dysautonomia conference centers biomarkers and post-exertional malaise
The 14th annual Dysautonomia International conference outside Houston included presentations on the role of autoimmunity in dysautonomia and a biobank initiative for POTS research.
-
How to interpret clinical trial results for Long COVID
With no proven treatments or cures, many people with Long COVID are turning to off-label medications, supplements, and medical devices to treat their symptoms. There are numerous options — and some of them even have clinical trials underway or are reporting results. But even if one study suggests a treatment might work, another might contradict…
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance